Jacobson Pharma, JBM Renew Logistics, Manufacturing Agreements

MT Newswires Live03-09

Jacobson Pharma (HKG:2633) and JBM (Healthcare) (HKG:2161) renewed logistics and manufacturing services agreements for three years from April 1, 2026, to March 31, 2029, according to a March 6 joint Hong Kong bourse filing.

Under the agreements, the Jacobson group will continue providing logistics services to the JBM group, while the JBM group will provide manufacturing services for certain generic drugs to Jacobson.

Annual caps for the logistics services are set at HK$8 million for the year ending March 2027, HK$9 million for 2028, and HK$10 million for 2029.

Caps for the manufacturing services are HK$7 million, HK$8 million, and HK$9 million for the respective years, the filing said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment